Description

D-Tyrosinamide, 4-chloro-N-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-phenylalanyl-D-cysteinyl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-L-phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-lysyl-L-threonyl-L-cysteinyl-, cyclic (2→7)-disulfide is a sophisticated, high-purity synthetic peptide conjugate designed for advanced research and diagnostic applications. Its complex structure, incorporating a DOTA-like chelating moiety and a cyclic disulfide bridge, provides unique properties for targeted molecular imaging and therapeutic development. This compound is essential for researchers and developers in pharmaceutical R&D, radiopharmaceutical synthesis, and molecular biology, where precise targeting and stable complexation are critical.

Application

• Radiopharmaceutical Precursor: Serves as a key intermediate for the synthesis of peptide-based radiopharmaceuticals, particularly for labeling with diagnostic or therapeutic radionuclides (e.g., Lutetium-177, Gallium-68).
• Molecular Imaging Probes: Used in the development of targeted contrast agents for Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT) imaging.
• Targeted Drug Delivery Systems: Functions as a targeting ligand in the design of conjugates that deliver cytotoxic agents or other therapeutic payloads to specific cells or tissues.
• Biochemical Research: Employed as a high-affinity chelator in studies of metal ion transport, enzyme inhibition, and receptor-ligand interactions.
• Theragnostic Development: A core component in the creation of theragnostic platforms that combine diagnostic imaging and targeted therapy into a single agent.
• Peptide Engineering: Used as a model compound in advanced peptide synthesis and structure-activity relationship (SAR) studies due to its complex architecture.

Basic Information

Item	Details
Product Name	D-Tyrosinamide, 4-chloro-N-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-phenylalanyl-D-cysteinyl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-L-phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-lysyl-L-threonyl-L-cysteinyl-, cyclic (2→7)-disulfide
CAS No.	1039726-31-2
Molecular Formula	C78H106ClN19O26S2
Molecular Weight	~1769.46 g/mol
Synonyms	DOTA-TATE Analogue; DOTA-conjugated Peptide; Cyclic Disulfide Peptide-DOTA Conjugate; D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2 (DOTA derivative); 1039726-31-2; DOTA-(Tyr3)-Octreotate derivative; Peptide-based Chelator; DOTA-Peptide Cyclic Disulfide
EINECS	Contact for details

Quality Control

This high-value peptide conjugate is manufactured under strict quality control protocols to ensure batch-to-batch consistency and purity suitable for research and pre-clinical applications. Identity and purity are confirmed via advanced analytical techniques including HPLC, Mass Spectrometry (MS), and NMR. A comprehensive Certificate of Analysis (COA) detailing purity, assay, and impurity profiles is provided with each shipment to support your regulatory and research documentation needs.

Storage

Preserve in a tightly closed container, protected from light. Store at -20°C or below. This product is hygroscopic (moisture-sensitive). Allow the vial to reach room temperature in a desiccator before opening to minimize moisture uptake. For long-term storage, keep desiccated under an inert atmosphere.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (HPLC)	Conforms to reference standard
Identification (MS)	Conforms to theoretical mass
Purity (HPLC)	≥ 95.0%
Assay (HPLC)	≥ 90.0% (on anhydrous basis)
Water Content (KF)	≤ 5.0%
Single Unknown Impurity	≤ 1.0%
Total Impurities	≤ 5.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.